Oral Disease Articles & Analysis
10 news found
Small molecule drugs have a proven track record of success in treating a wide range of diseases, including cancer, cardiovascular disorders, and infectious diseases. By leveraging the potential of small molecules, our clients can benefit from: Targeted Therapies - Small molecules can be designed to selectively modulate specific biological targets, allowing for ...
In parallel, there was improved motor function in the treated mice compared to the baseline and vehicle control groups supporting the therapeutic efficacy of OLX-07010. “As an oral small molecule, our lead program is a highly differentiated approach that targets tau self-association, the beginning stages of the tau aggregation cascade, for the treatment of ...
(CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to report a significant potential market opportunity for its oral dissolvable (“ODF”) biosensor screening tests for oral inflammation. ...
OFF episodes are an unmet medical need with a great impact on the quality of life of Parkinson’s disease patients. Oral levodopa does not prevent the occurrence of OFF episodes, nor enables their fast resolve, mainly because of a highly variable and unreliable absorption through this route of administration. ...
” Initial studies in two mouse models, representative of tau aggregation in Alzheimer’s (htau) and rare neurodegenerative diseases (P301L tau JNPL3), have shown that oral administration of OLX-07010 to young mice prevented the self-association of tau and the accumulation of large insoluble aggregates of tau associated with neurodegenerative ...
Results further support the benign safety profile of VE202 and identify an optimal dosing regimen Vedanta plans to initiate a Phase 2 clinical trial of VE202 in ulcerative colitis patients in the second half of 2021 Vedanta Biosciences, a leading clinical-stage microbiome company developing a new category of oral therapies using defined bacterial consortia manufactured from ...
This is especially important in our goal to bring P-21 to patients as a potentially promising non-injectable treatment to address cardiovascular diseases.” Having high blood cholesterol raises the risk for heart disease, the leading cause of death, and for stroke, the fifth leading cause of death. High total cholesterol (≥ 240 mg/dL) doubles the risk of ...
Invest, New England Journal of Medicine, The Lancet Infectious Diseases and more. The results from the ACTT-2 clinical trial led to baricitinib being granted FDA emergency use authorisation in November, making it the first AI-derived hypothesis for a COVID-19 treatment validated in a large international randomised trial that received Emergency Use Authorisation in this ...
Alkahest Inc., a clinical stage biotechnology company focused on discovering and developing transformative therapies to treat age-related diseases, today announced an oral presentation of data from its phase 2a study ALK6019-201 in mild-to-moderate Alzheimer’s Disease at the 12th Clinical Trials on Alzheimer’s Disease ...
It is vital for people throughout the world to continue to have access to a safe, durable, affordable treatment for tooth decay.The ADA is also delighted that the proposed treaty recognizes the need for national programs to prevent oral disease and calls for more research into developing new treatment options.Long term, it is critically important to raise global ...